

This is an overview about all ongoing clinical trials of the CCCA and the cooperating network partners.

To find the right contact person, please orientate yourself here at the respective study and the named study site. >>[Detailed contact information can then be found at 'ISCO | Contact Information'](#).

Indication	Study	Study site
CUP Syndrom		
Indication	Study	Study site
CUP 1st-Line	CUPISCO MX39795 A phase II, randomized, active-controlled multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum doublet chemotherapy.	UKA Dept. of Internal Medicine II
Skin Cancer		
Indication	Study	Study site
Melanoma	NivoMela Adjuvant nivolumab treatment in stage II high-risk melanoma - A randomized, controlled, phase III trial with biomarker-based risk stratification.	UKA Dept. of Dermatology
Melanoma	Pivotal/Philogen A pivotal Phase III, open label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients.	UKA Dept. of Dermatology
Melanoma	SNEPS Randomized Trial Comparing Sentinel Lymph Node Excision (SLNE) with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in Melanoma.	UKA Dept. of Dermatology

Indication	Study	Study site
Melanoma	Nivo-Pass Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice	UKA Dept. of Dermatology
Malignant Melanoma	ADOREG Nationwide prospective registry for health services research in dermatologic oncology Indication: Malignant melanoma from stage IIB, epithelial skin tumors, actinic keratosis.	UKA Dept. of Dermatology
Merkel Cell Carcinoma	MCC-Trim Noninterventional cohort registry study to assess characteristics and management of patients with merkel cell carcinoma in Germany.	UKA Dept. of Dermatology
Advanced Melanoma	NIS-NICO A national, prospective, non-interventional study (NIS) of Nivolumab monotherapy or in combination with Ipilimumab in patients with advanced melanoma and in Patients with adjuvant Nivolumab therapy.	UKA Dept. of Dermatology
Melanoma	Combi-EU BRAF-/MEK-Inhibition with Dabrafenib and Trametinib in Melanoma patients in the adjuvant setting:a noninterventional observatory Study.	UKA Dept. of Dermatology
BRAFV600-mutated melanoma	Bering Melanoma Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, multi-national, prospective, longitudinal, non-interentional study in Germany and Austria.	UKA Dept. of Dermatology

Indication	Study	Study site
Gastrointestinal Cancer/Liver and Pancreatic Cancer		
Indication	Study	Study site
CRC, metastasized	FIRE4 A randomised phase III study to assess the efficacy of cetuximab rechallenging in patients with metastatic colorectal cancer.	UKA Dept. of Internal Medicine II UKA Dept. of Internal Medicine III Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Colorectal carcinoma	BNT000-001 Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Colorectal carcinoma	Supportive Care Trial evaluating the prevalence of malnutrition in centralized care of patients with colorectal carcinoma	Medical center Ostallgäu-Kaufbeuren
Colorectal carcinoma	ColoPredict Plus 2.0 Register Retro and prospective evaluation of the role of MSI and KRAS regarding the prognosis of patients with stage I-III colorectal carcinoma.	Medical center Ostallgäu-Kaufbeuren Medical center Aichach-Friedberg
Metastatic gastrointestinal cancer	GOBLET A phase 1 / 2 multiple - indication biomarker, safety, and efficacy study in advanced of metastatic Gastrointestinal cancers exploring treatment combinations with Pelareorep and a Tezolizumab.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
	completely list follows	
Hematological Neoplasms		
Indication	Study	Study site

Indication	Study	Study site
ALL	GMALL 08-2013 A phase III study, therapy optimization in adult patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma through individualized, targeted and intensified therapy.	UKA Dept. of Internal Medicine II
ALL	All-Register Frankfurt Register Study Report of all patients with ALL.	UKA Dept. of Internal Medicine II
Myelofibrosis	TRANSFORM-2 A Randomized, Open-label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
CLL	CLL2-BZAG A prospective, open-label, multicenter phase - II trial to evaluate the efficacy and safety of a sequential regimen of bendamustin followed by obinutuzumab (GA101), zanubritinib (BFB-3111) and venetoclax (ABT-199).	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Diffuse large B-cell lymphoma (DLBCL)	FrontMind A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing to efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).	UKA Dept. of Internal Medicine II
ALL	DaunoDouble A phase III study. Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of induction therapy for adult patients with acute myeloid leukemia ≤ 65 years.	UKA Dept. of Internal Medicine II

Indication	Study	Study site
AML	Etal3-ASAP A phase III study. Evaluation of the impact of remission induction chemotherapy prior to allogeneic stem cell transplantation in relapsed and poor-response patients with AML.	UKA Dept. of Internal Medicine II
AML	AML register and biomaterial database of the Study Alliance Leukemia (SAL) and the AML Cooperative Group (AML-CG).	UKA Dept. of Internal Medicine II
AML MDS	PALOMA Primary compArison of LiposOmal Anthracycline based treatment versus conventional care strategies before allogeneic stem cell transplantation in patients with higher risk MDS and oligoblastic AML – the PALOMA study, phase III.	UKA Dept. of Internal Medicine II
APL	Apollo A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemia.	UKA Dept. of Internal Medicine II
CML	BlastCrisis Register Multicentric prospective and retrospective register study, collecting patient with CML blast crisis diagnosed in Germany and Europe.	UKA Dept. of Internal Medicine II
CML	Ponderosa Observational phase IV study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose.	UKA Dept. of Internal Medicine II

Indication	Study	Study site
Aggressive B- and T-cell lymphoma, primary progressive or relapsed	ASTRAL An open, randomized Phase III clinical study to compare standard versus predefined use of plerixafor for mobilization of autologous peripheral blood stem cells and to compare autologous with allogeneic stem cell transplantation as treatment of primary progressive and relapsed aggressive Non-Hodgkin Lymphoma via risk adapted stratification. Allogeneic Stem Cell Transplantation in Relapsed Aggressive Non-Hodgkin Lymphoma (ASTRAL).	UKA Dept. of Internal Medicine II
Aggressive Lymphoma	GOAL II A prospective, multicenter randomized phase II trial investigating Gemcitabine / Oxaliplatin / Rituximab with or without Mor208 for patients with relapsed /refractory aggressive lymphoma.	UKA Dept. of Internal Medicine II
Non-Hodgkin Lymphoma	CHARLY Phase-II study on the value of post-transplant cyclophosphamide after haplo-identical stem cell transplantation for poor-risk non-Hodgkin lymphoma (CHARLY Trial).	UKA Dept. of Internal Medicine II
Advanced stage Hodgkin lymphoma	HD-21 Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD. A phase II study.	UKA Dept. of Internal Medicine II Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
MDS	CMBG453B12301/Stimulus2 A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2).	UKA Dept. of Internal Medicine II

Indication	Study	Study site
Multiple myeloma	Caro Therapy with carfilzomib in combination with lenolidamide and dexamethadone for patients with multiple myeloma, prospective only. Non-interventional study (NIS).	UKA Dept. of Internal Medicine II
Myeloid Neoplasms	GSG-MPN-Registerstudy German MPN-Registry for BCR-ABL1-Negative Myeloid Neoplasms.	UKA Dept. of Internal Medicine II
Lung and Thoracic Cancer		
Indication	Study	Study site
SCLC	SCLC-ZIS Multicenter Real World Analysis of Non-Small Cell Lung Cancer Patients with EGFR and HER2 Exon 20 Insertion Mutations, a non-interventional study (NIS).	UKA Dept. of Internal Medicine II
NSCLC	Vargado-NIS second-line therapy for advanced or metastatic adenocarcinoma of the lungs, non-interventional study (NIS).	UKA Dept. of Internal Medicine II
NSCLC metastatic to the brain	Break B5 A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous non-small-cell lung cancer (NSCLC) metastatic to the brain.	UKA Dept. of Internal Medicine II
Pleural mesothelioma	NICITA Nivolumab with chemotherapy in pleural mesothelioma after surgery, phase II study.	UKA Dept. of Internal Medicine II
Breast and Gynecological Cancer		
Indication	Study	Study site

Indication	Study	Study site
Breast cancer	DESTINY A phase 3, multicenter, randomized, open-label, active-controlled study of Trastuzumab Deruxtecan (T-DXd) versus Trastuzumab Emtansine (T-DM1) in subjects with high-risk Her2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Early breast cancer	ADAPTlate A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - adjusted Personalized Therapy comparing abemaciclib combinet with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, HR+ / HER2-early breast cancer.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Breast cancer	EUBREAST-01 Omission of sentinel lymph node biopsy in triple-negative and HER2-positive breast cancer patients with radiologic and pathologic complete response in the breast after neoadjuvant systemic therapy: a single-arm, prospective surgical trial.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Breast cancer	neoMono An adaptive randomized neoadjuvant two arm trial in triple-negative breast cancer comparing a mono Atezolizumab window followed by a Atezolizumab - CTX therapy with Atezolizumab - CTX therapy.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Breast cancer	Detect V / Chevendo A multicenter, randomized phase III study to compare chemo-versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin (trastuzumab) and Perjeta (pertuzumab) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.

Indication	Study	Study site
Breast cancer	SASCIA Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA	Hematological oncological practice Heinrich, M.D./Bangerter, M.D.
Breast and ovarian cancer	BRandO-Bio Registry trial evaluating the biologic disease profile and the clinical course in breast and ovarian cancer patients	Medical center Ostallgäu-Kaufbeuren
	completely list follows	
Sarcoma		
Indication	Study	Study site
Osteosarcoma	COSS - Register Study Register of the Cooperative Osteosarcoma Study Group COSS	UKA Dept. of Internal Medicine II
Urogenital Cancer		
RCC, advanced metastasized	NORA This is a German non-interventional, nationwide, prospective, observational, multicenter study in patients diagnosed with advanced/metastatic RCC with clear-cell and non-clear-cell histology, who start a new systemic 1st line therapy with nivolumab and ipilimumab combination therapy in intermediate/poor risk patients (cohort 2) or nivolumab monotherapy after prior therapy (cohort 1) within the market authorization approval.	UKA Dept. of Internal Medicine II
RCC	CARAT National, observational, open, prospective, longitudinal, multicenter cohort, non-interventional study. Patients with mRCC requiring systemic treatment intervention.	UKA Dept. of Internal Medicine II

Indication	Study	Study site
Prostata cancer	TRITON3 A multicenter, Randomised, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency.	Hematological oncological practice Heinrich, M.D./ Bangerter, M.D.
Prostata cancer	PCO Studie: Prostate Cancer Outcomes Study The "Prostate Cancer Outcome" aims to contribute to improving the physical and mental health of men being treated for localised prostate cancer.	UKA Dept. of Urology
Prostata cancer	IMPROVE Studie: Importance of various supportive measures in the context of radical prostatectomy from the patient's perspective Prospective questionnaire study to evaluate the importance of various supportive measures in the context of radical prostatectomy from the patient's perspective	UKA Dept. of Urology
CNS-Tumors		
Glioblastoma	Intrago II A multicenter randomized phase III trial on Intraoperative Radiotherapy in newly diagnosed Glioblastoma multiforme (INTRAGO II)	UKA Dept. of Radiotherapy
Other Clinical Trials		
Metastatic solid tumors	ALPS Augsburg Longitudinal Plasma Study (ALPS) for the evaluation of Liquid Biopsy (LBx) as a tool for diagnostic support, detection of disease progression and for the identification of mutations in treatment settings of patients receiving palliative systemic treatment for solid neoplasia. Non-interventional study.	UKA Dept. of Internal Medicine II

Indication	Study	Study site
Immune thrombocytopenia	<p>XPAG-ITP</p> <p>This is a Phase II, multicenter, randomized (1:1), open-label study to compare the efficacy and safety of eltrombopag in combination with a short course of high-dose dexamethasone to 1-3 cycles of high-dose dexamethasone monotherapy, as first-line treatment in adult patients with newly diagnosed ITP. Randomization to treatment will follow a 1:1 ratio.</p>	UKA Dept. of Internal Medicine II